Pyxis Oncology (PYXS) Shares Outstanding (Weighted Average) (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Shares Outstanding (Weighted Average) data on file, last reported at $62.1 million in Q4 2025.

• Shares Outstanding (Weighted Average) for Q4 2025 came in at $62.1 million, up 6.33% year-over-year; the trailing twelve-month figure through Dec 2025 was $62.1 million (up 6.33% YoY), and the FY2025 annual result was $62.1 million, up 6.33% from the prior year.
• Shares Outstanding (Weighted Average) improved to $62.1 million in Q4 2025 per PYXS's latest filing, from $641720.0 in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $62.1 million in Q4 2025 and troughed at $641720.0 in Q3 2025.
• A 5-year average of $27.3 million and a median of $32.4 million in 2022 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Weighted Average) slumped 96.1% in 2024, then jumped 3716.14% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $8.5 million in 2021, then surged by 288.93% to $33.0 million in 2022, then rose by 20.8% to $39.9 million in 2023, then surged by 46.46% to $58.4 million in 2024, then gained by 6.33% to $62.1 million in 2025.
• Business Quant data shows PYXS's Shares Outstanding (Weighted Average) at $62.1 million in Q4 2025, $641720.0 in Q3 2025, and $61.5 million in Q2 2025.